Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.